# Virtue

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/virtue

- Industry: Medical Devices & Equipment
- Headquarters: Suzhou, China
- Total disclosed funding: $131M
- Latest round: Series B (Jan 6, 2022)
- Investors on record: 6

## About

Established in 2019 and based in Suzhou, China, Virtue operates as an in vitro diagnostic technology and product developers that provides in vitro diagnostic technology and product. PerkinElmer is the strategic partner of the company. The company has promoted triple quadrupole mass spectrometry detection system QSight 420MD in 2021.

The company provides clinical solution from early screening, diagnosis, treatment monitoring to prognosis management. The company focuses on infectious diseases, tumors, women and children, and chronic diseases. The company also provides platform that includes clinical mass spectrometry, panoramic pathology and molecular diagnosis.

The company will put the funding towards technology platform R&D and in vitro diagnosis business expansion.

## Funding rounds

- Series B, Jan 6, 2022, $100M — Hong Shan, Lilly Asia Ventures, 5Y Capital, Oriza Holdings, PKI Ventures
- Series A, Dec 16, 2020, $31M — Lilly Asia Ventures, PerkinElmer U.S. LLC

## Investors

- Lilly Asia Ventures (https://capitalatlas.ai/funds/lilly-asia-ventures) — Series A, Series B
- PerkinElmer U.S. LLC — Series A
- Hong Shan — Series B
- 5Y Capital (https://capitalatlas.ai/funds/5y-capital) — Series B
- Oriza Holdings (https://capitalatlas.ai/funds/oriza-holdings) — Series B
- PKI Ventures — Series B